Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Income from Continuing Operations came in at 10354000.0 in Q1 2026, up 18.72% year-on-year from 8721680.47 in Q1 2025, and down 20.02% quarter-over-quarter from 8627000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 10354000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 18.72% year-over-year to 10354000.0 in Q1 2026; TTM through Mar 2026 was 42236000.0, a 29.57% increase from a year earlier, with the FY2025 full-year figure at 116540000.0, down 105.96% from the prior year.
- Income from Continuing Operations declined to 10354000.0 in Q1 2026 per RANI's latest filing, from 8627000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 8627000.0 in Q4 2025 and bottomed at 18664000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 14779000.0 (2024), against an average of 14602411.76.
- Across the five-year window, Income from Continuing Operations slumped 191.08% in 2022 and surged 45.13% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 17372000.0 in 2022, then increased by 19.09% to 14055000.0 in 2023, then retreated by 11.86% to 15722000.0 in 2024, then surged by 45.13% to 8627000.0 in 2025, then decreased by 20.02% to 10354000.0 in 2026.
- Per Business Quant, the three latest RANI Income from Continuing Operations figures stand at 10354000.0 (Q1 2026), 8627000.0 (Q4 2025), and 11959000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | -10.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.35 Mn |
| Dec 31, 2025 | -8.63 Mn |
| Sep 30, 2025 | -11.96 Mn |
| Jun 30, 2025 | -11.30 Mn |
| Mar 31, 2025 | -12.74 Mn |
| Dec 31, 2024 | -15.72 Mn |
| Sep 30, 2024 | -18.05 Mn |
| Jun 30, 2024 | -13.46 Mn |
| Mar 31, 2024 | -14.78 Mn |
| Dec 31, 2023 | -14.06 Mn |
| Sep 30, 2023 | -18.33 Mn |
| Jun 30, 2023 | -18.66 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -17.37 Mn |
| Sep 30, 2022 | -16.21 Mn |
| Jun 30, 2022 | -15.97 Mn |
| Mar 31, 2022 | -13.83 Mn |
| Dec 31, 2021 | -13.31 Mn |
| Sep 30, 2021 | -28.70 Mn |
| Jun 30, 2021 | -5.49 Mn |